Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05114096

Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)

Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities in preterm infants, such as respiratory distress syndrome.

The standard of care for pregnant people at risk of preterm birth includes 2 doses of Celestone (for a total of 24 mg in Canada, or 22.8 mg in Australia) to accelerate fetal lung maturity.

The investigators plan to conduct a randomized controlled trial to determine whether half the usual dose (12 mg in Canada, or 11.4 mg in Australia) of Celestone is non-inferior to the standard double doses.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–55 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

University of Calgary, Cumming School of Medicine, Calgary, Alberta, Canada

Loading trial locations.

About this study

Preterm infants are at risk of mortality and morbidity. Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities, such as respiratory distress syndrome.

The standard of care for pregnant people at risk of preterm birth includes 2 doses of Celestone to accelerate fetal lung maturity (total 24 mg in Canada, 22.8 mg in Australia). There are no published clinical trial data on the benefits or risks of a single dose of antenatal corticosteroid vs. standard double doses (Ninan et al JOGC 2020).

Pregnant people at 22 weeks and 0 days to < 34 weeks and 6 days' gestation at risk of preterm birth with a singleton or twin gestation who have received the first dose of Celestone and consented to the trial will be randomized to receive approximately 24 hours later either an experimental placebo injection (of normal saline) or the standard double dose of Celestone to determine whether the intervention is non-inferior for the primary outcome of a composite of perinatal mortality or substantial morbidity.

Please note: Based on Health Canada's' guidance the study phase is 'Other: Off-Label use'. However, on the clincaltrial.gov record, 'Phase 4' is selected as this is the most relevant phase and there is no option to select 'Other'.

Please note: McMaster University, Canada is the Canadian Regulatory Sponsor and Overall Sponsor, and the University of Adelaide Australia is the Australian Sponsor.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant people, aged 18 to 55 years old, at risk of preterm birth with a singleton or twins between 22 weeks and 0 days and <34 weeks and 6 days gestation who have received only a single dose of Celestone within 24 hours
  • Capable of giving informed, written consent.

Exclusion criteria

  • Contraindication to corticosteroids
  • Systemic corticosteroids for medical conditions during the pregnancy (e.g. lupus, severe asthma, Covid, etc).
  • Previous participation in this trial (in a previous pregnancy)
  • Known severe/life-threatening fetal or pregnant patient condition (e.g. fetal congenital/chromosomal abnormality)
  • Demise of one or more fetuses after 14 weeks and 0 days

Treatment and study plan

Celestone + placebo

Drug

After the first intramuscular injection of Celestone, participants randomized to the "Placebo Comparator" group will receive 1 intramuscular injection of placebo.

Celestone + Celestone

Drug

After the first intramuscular injection of Celestone, participants randomized to the "Active Comparator" group will receive 1 intramuscular injection of Celestone.

Primary outcomes

  1. Perinatal Mortality or Substantial Neonatal Morbidity

    Time frame: approximately 1 month

    Fetal death post-randomization or in hospital neonatal death OR => 1 of respiratory morbidity (requiring surfactant <=48 hrs of life), severe intraventricular hemorrhage (distending/beyond the ventricles, i.e. Grade 3 or 4), or severe bowel problem (necrotizing enterocolitis, Stage 2 or 3)

Secondary outcomes

  1. Death or neurosensory/developmental impairment at 24 months

    Time frame: approximately 24 months

    Death or neurosensory/developmental impairment at 24 months (+/- 6 months; accounting for gestation at birth), mood (anxiety/depression), behavior (aggression), etc as assessed by:

    • Ages and Stages Questionnaire-3 (ASQ)
    • Child Behavior Checklist: 4 subscales
    • Physician diagnosis of cerebral palsy (parent report).

Other outcomes

  1. Number of babies who received intubation and duration of invasive mechanical ventilation

    Time frame: approximately up to first 6 months of life

    Number of babies who received intubation and duration of invasive mechanical ventilation

  2. Number of babies who received, and duration of, supplemental oxygen (after resuscitation) and other ventilatory support

    Time frame: approximately up to first 6 months of life

    Number of babies who received, and duration of, supplemental oxygen (after resuscitation) and other ventilatory support

  3. Number of babies with respiratory distress after the initial resuscitation/stabilization and main cause

    Time frame: approximately 1 month

    Number of babies with respiratory distress after the initial resuscitation/stabilization and main cause (such as respiratory distress syndrome, pneumothorax/pneumomediastinum, pneumonia, transient tachypnea of the newborn, meconium aspiration syndrome, persistent pulmonary hypertension of the newborn)

  4. Number of babies with Respiratory distress after the initial resuscitation/stabilization and main cause

    Time frame: approximately at birth

    Respiratory distress after the initial resuscitation/stabilization and main cause (such as respiratory distress syndrome, pneumothorax/pneumomediastinum, pneumonia, transient tachypnea of the newborn, meconium aspiration syndrome, persistent pulmonary hypertension of the newborn),

  5. Number of babies with hypoglycemia

    Time frame: 48 hours

    Number of babies with hypoglycemia (low plasma glucose < 2.6 mmol/L between 30 minutes and 48 hours of life)

  6. Number of babies with neonatal sepsis

    Time frame: 7 days

    Number of babies with neonatal sepsis within 7 days of birth, defined as a positive (bacterial, viral or fungal): blood culture or cerebrospinal fluid culture (or gram stain) or urine culture by sterile collection.

  7. Number of babies with severe retinopathy of prematurity needing treatment

    Time frame: approximately first few months of life

    Number of babies with severe retinopathy of prematurity defined as requiring vascular endothelial growth factor (VEGF) or laser or cryotherapy per the local guidelines

  8. Number of babies with patent ductus arteriosus (PDA) needing a closure procedure (surgery or device)

    Time frame: up to 12 weeks after birth

    Number of babies with patent ductus arteriosus (PDA) needing a closure procedure (surgery or device)

  9. Anthropometry at birth and at 24 months corrected age

    Time frame: at birth and at 24 months corrected age

    Weight (in grams), length (in centimeters), and head circumference (in centimeters) for birth week as ACS can impact growth

  10. Number of babies with severe late brain injury

    Time frame: up to 20 weeks postnatal

    Periventricular leukomalacia [PVL], i.e. cystic changes in white matter or porencephalic cysts or white matter changes diagnosed by ultrasound or MRI.

  11. Number of babies with chronic lung disease

    Time frame: approximately up to first 6 months of life

    Late respiratory morbidity, bronchopulmonary dysplasia (BPD), defined as requiring respiratory support or supplemental oxygen > 36 completed weeks' corrected gestation.

  12. Apgar score and cord blood pH

    Time frame: approximately at birth

    Apgar score (at 1 and 5 min) and lowest cord blood pH, regardless of whether arterial or venous.

  13. Length of stay in special care or an intensive care setting

    Time frame: approximately up to first 6 months of life

    Length of stay in an intensive care setting such as the neonatal intensive care unit (NICU).

  14. Use of postnatal corticosteroids

    Time frame: up to 20 weeks postnatal

    Use of systemic (intravenous or oral) postnatal corticosteroids and type (e.g. hydrocortisone, dexamethasone).

  15. Number of babies with longterm health care outcomes

    Time frame: approximately 5 -10 years

    Number of babies with reported longterm health care outcomes after initial hospital, such as hospitalizations, and other health care use.

  16. Number of babies with longterm education outcomes

    Time frame: approximately 5 -10 years

    Number of babies with reported longterm education or non-health data outcomes, collected through database linkage where possible.

  17. Number of participants with fetal death post-randomization or in hospital neonatal death OR => 1 of respiratory morbidity, severe intraventricular hemorrhage , or severe bowel problem

    Time frame: approximately 1 month

    Fetal death post-randomization or in hospital neonatal death OR => 1 of respiratory morbidity (requiring surfactant <=48 hrs of life), severe intraventricular hemorrhage (distending/beyond the ventricles, i.e. Grade 3 or 4), or severe bowel problem (necrotizing enterocolitis, Stage 2 or 3)

Study contacts

Contact information is provided by the study sponsor or research team.

SNACS Coordinating Centre

CONTACT

[email protected]

Sarah D McDonald, MD,MSc,FRCSC

CONTACT

[email protected]

905-525-9140 ext. 26622

Sponsors and collaborators

Lead sponsor

McMaster University

Other

Collaborators

  • Canadian Institutes of Health Research (CIHR)
  • Hamilton Health Sciences Corporation
  • Medical Research Future Fund
  • Sunnybrook Research Institute
  • University of Adelaide
  • Women's and Children's Hospital, Australia

Registry information

Official study title

Single Dose of Antenatal Corticosteroids (SNACS) Randomized Controlled Trial for Pregnancies at Risk of Preterm Delivery: To Keep Babies and Children Safe

Acronym: SNACS

Important dates

Study start
2023
Primary completion
2026
Study completion
2029
First posted
Nov 9, 2021
Registry last updated
Jan 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.